Sanofi returns rights to Sangamo program

7 January 2022

Sanofi (Euronext: SAN) will be returning rights to SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development for the treatment of sickle cell disease (SCD), back to Sangamo Therapeutics (Nasdaq: SGMO).

The Californian company is now exploring other options to advance the program, including seeking a new collaboration partner.

"We will vigorously investigate alternative options to bring this genomic medicine forward to patients"This transition follows Sanofi’s termination of the agreement between the companies to develop genomic medicines for hemoglobinopathies. The French company has elected to transition the SCD program to Sangamo following a recent change in its cell therapy strategy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK